Candel Therapeutics Inc (CADL)

[georgie18]

CADL...$13.19...🥳...Watch for All Time highs here...

georgie18

Member Level
Re: georgie18 post# 32234

Thursday, February 20, 2025 10:01:31 AM

Post#
32302
of 32319
CADL...$12.33...🥳...Another Runner on the Cup N Handle Breakout...

georgie18

Member Level
Re: georgie18 post# 178

Wednesday, February 19, 2025 11:56:55 AM

Post#
179
of 179
CADL...$10.60...🥳...Cup N Handle Breakout....Off my $7 range Alert...

georgie18

Member Level
Re: georgie18 post# 30792

Tuesday, February 18, 2025 9:52:58 AM

Post#
32134
of 32233
CADL...$10.07...🥳...Cup N Handle in play here...Watch for $14.85 Breakout...imo...we shall see...

georgie18

Member Level
Re: georgie18 post# 160

Wednesday, January 22, 2025 10:41:18 AM

Post#
165
of 177
CADL...Added a load under $7...🥳... Cup N Handle Pattern ...Looking for Triple Top Breakout at $14.85 Range... https://schrts.co/spDmKkki

georgie18

Member Level
Re: None

Thursday, January 16, 2025 3:45:04 PM

Post#
671612
of 671947
CADL...$7.81...🥳...50/100 Ready to Cross the 200... https://schrts.co/nPxatndN

On track to report updated overall survival data for CAN-2409 from phase 2a clinical trials in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), expected in Q1 2025
Preparations for Biologics License Application (BLA) for CAN-2409 in prostate cancer underway, with submission expected in Q4 2026
The Company intends to present phase 3 clinical trial data from CAN-2409 in prostate cancer at upcoming scientific conferences
On track to report overall survival data in patients with recurrent high-grade glioma (rHGG) from ongoing phase 1b trial evaluating multiple doses of CAN-3110, expected in Q4 2025
The Company expects that its cash and cash equivalents of approximately $103M (unaudited) as of December 31, 2024, will be sufficient to fund its current operating plan into Q1 of 2027
NEEDHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today highlighted recent successes across the Company's viral immunotherapy portfolio and provided an update on the Company’s cash position and upcoming 2025 milestones.